BridgeBio Pharma, Inc. (BBIO) Competitors & Peers
The 5 largest companies in the same industry as BridgeBio Pharma, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $550.87 | P/E 35.5RSI 59Cap 139.8 B |
| REGN | Peer | $919.96 | P/E 20.3RSI 63Cap 95.2 B |
| ARGX | Peer | $962.27 | P/E 33.3RSI 62Cap 60.7 B |
| RVMD | Peer | $200.15 | RSI 55Cap 42.6 B |
| CSLLY | Peer | $35.11 | P/E 18.2RSI 71Cap 66.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- BAYN.DESupplier
Own 10-Q customer-concentration disclosure: Bayer = 20% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - LIANYSupplier
Own 10-K customer-concentration disclosure: LianBio = 14% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - BAYRYSupplier
Own 10-Q customer-concentration disclosure: BayerConsumerCareAG = 60% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - 4151.TSupplier
Own 10-Q customer-concentration disclosure: KyowaKirinCo.Ltd = 75% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- ALNYCompetitor
BridgeBio's acoramidis competes with Alnylam's RNAi drugs for amyloidosis treatment.
Model-inferred, unverified — treat as a lead, not evidence